drugset / Trial / NCT05184322
XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults
Phase 1
Completed
87 enrolled
Sciwind Biosciences APAC CO Pty. Ltd.
Hangzhou Sciwind Biosciences Co., Ltd. · collabSciwind Biosciences USA Co., Ltd. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
XW004 is an acylated human glucagon-like peptide 1 (GLP-1) analogue and is being developed for type 2 diabetes mellitus (T2DM) and obesity management.
Timeline
- Start
- 2022-04-12
- Primary completion
- 2024-07-13
- Completion
- 2025-03-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ecnoglutide | Protein / enzyme biologic | — | Oral |